Emerging Company Showcase

1. Curtiss Healthcare
Animal Health Asia
Hong Kong, October 2016
Thomas Bigger, CEO
1HealthCare
A New World of Health

2. Curtiss Healthcare Highlights & Near
Term Milestones
 Founded in 2015 to commercialize research of Prof Roy Curtiss lll
 Develop novel vaccines to prevent critical infectious diseases in
animals & humans
 Orally delivered Live Recombinant Attenuated Salmonella Vector
(RASV) Vaccines
 $1.4M in seed capital raised to date
 >100 issued patents licensed exclusively from 3 universities
 Series A to raise $12 - $15M to advance 5 - 6 vaccines
 In advanced discussions with several prospective AgPharma partners
2
HealthCare
A New World of Health

3. Exclusive Licenses Consolidated IP from
3 World Class Universities
Washington Arizona State University
University University of Florida
3
HealthCare
A New World of Health

4. What is Unique About Curtiss
Healthcare’s Offering
Unique Technology:
 Disruptive vaccine technology
 Single vector affords multiple pathogen protection
 Auto lysing or self destruction (minimizes host & environmental effects)
 Vector proven safe in multiple species
Meets Market Needs:
 Avoids/address concerns about antibiotic resistance
 Delivered orally
 Utilizes conventional manufacturing process
 Economic benefit to producers
4

5. Curtiss’ Technology Initially Focused on
Improving Food Safety and Food Quality
Why Food Safety and Food Quality (FS/FQ)
 Increased expectations for food safety & antibiotic free
products from major buyers and end consumers
 Middle class growth expanding globally with similar
food quality demands in established & growing markets
 FS/FQ is key pillar for growth in all 3 leading food
producing animal franchises
 Majority of unmet targets are bacterial, where industry’s
portfolio is deficient while antibiotic use being curtailed
5 HealthCare
A New World of Health
Trader Joe's urged to drop
meat from animals raised with
antibiotics
Publicized “No Antibiotics
Ever” campaign in 2015
McDonalds to cut use of
antibiotics in chicken

6. Value of Controlling Human Food-Borne
Illnesses
 Food producing animals contribute more than $300 billion in
revenues to the U.S. economy
 Food-borne illnesses cost U.S. economy $15 billion annually*
 CDC estimates there are 48 million food-borne infections in the
U.S. each year
 Leading approaches to combat food-borne illnesses
 Improving food handling techniques, personal hygiene and
sanitary engineering
 Vaccines
 >$5 billion currently spent to control bacterial infections in food
producing animals
6
* USDA estimates
HealthCare
A New World of Health

7. Why Vaccines Are So Important for
Agricultural Animals?
 Bacterial infections will always be present in agriculture
 Prevent many different bacterial infections and reduce the need
for broad antibiotic use
 Convenient and easy to use
 Prevent development of antimicrobial resistance
 Economic benefit to producers
7
HealthCare
A New World of Health

8. Why Use Salmonella as a Vaccine Vector?
 Highly efficient invader in the gastro-intestinal tissues of target species
 Vector attaches to mucosal lymphoid tissues and colonizes internal
lymph nodes, liver & spleen
 Produces robust immune stimulation and long-term protective
immunity
 Easily manipulated genetically which facilitates vaccine design
 Curtiss Healthcare has a broad IP position using Salmonella in
vaccines in animals and humans
8
HealthCare
A New World of Health

9. Why Is Curtiss Healthcare’s RASV Platform
Needed Today?
9 HealthCare
A New World of Health
 Current vaccines not ideal for initial target infections
 Current treatment for target infections is intensive use of antibiotics
 Market and regulatory pressure to curtail or eliminate use of
antibiotics
 Convenient oral delivery (in feeds, water or by spray)
 Maximum immunity with minimal reactivity
 Self-destruct, eliminating shedding and spreading
 Provides cost effective return for producer

10. Curtiss Is Targeting Key Markets in FS & FQ -
Initial Products in Avian & Swine
10
HealthCare
A New World of Health
 Avian products to reduce food-borne pathogens and
improve bird health and growth
 C. perfringens (Necrotic Enteritis)
 Campylobacter
 Salmonella
 E. coli
 Swine disease is often subclinical and leads to
productivity loss and increased costs
 Helicobacter
 Lawsonia
 E. coli

11. Initial Avian and Swine FS & FQ Products
Represent Substantial Revenue Potential
 Avian (birds) products to reduce food-borne
pathogens and improve bird health and growth
 C. perfringens (Necrotic Enteritis)
 Campylobacter
 Salmonella
 E. coli
 Swine (pigs) disease is often subclinical and leads to
productivity loss and increased costs
 Helicobacter
 Lawsonia
 E. coli
Total Peak U.S. Sales Potential of 6 Initial Programs:
11
HealthCare
A New World of Health
U.S. Peak
Annual Sales*
$35 million
$60 million
$40 million
$20 million
$35 million
$45 million
$10 million
$235 million
* U.S. product sales estimates by Prospective Pharma Partner

12.  Necrotic enteritis (NE) disease is widespread in broilers, causes diarrhea,
high morbidity and mortality 10 - 40%
 Clostrium perfringens is a gram-positive, spore-forming, rapidly growing
anaerobe
 Sub-clinical form is most prevalent cause of reduced growth performance
 Affects chickens beginning soon after hatch until death
 NE is expected to increase with elimination/reduction of antibiotic use
Curtiss Healthcare’s Most Advanced Product
Targets Necrotic Enteritis caused by C. perfringens
12 HealthCare
A New World of Health
Healthy Chicks

13. Proof of Efficacy in Necrotic Enteritis
Salmonella enterica / Clostridium perfringens Vaccine #2:
In consecutive studies using a single oral vaccination of chicks on
the day of hatch results indicate:
 Statistically significant protection from mortality; in a “real world”
model, including a C. perfringens - coccidia pre-challenge
 Statistically significant protection from development of lesions
from C. perfringens
 A dose dependent effect in protection, supporting the studies
 Improved body weights and feed conversion ratios - comparable
to the standard antibiotic treatment
13
HealthCare
A New World of Health

14. Business Strategy
 Initial opportunities for Proof of Concept for RASV technology in
avian market (and then porcine, bovine & companion animals)
 Partner initial products to generate cash flow
 Identify and develop human Salmonella-based vaccines for infectious
diseases (i.e. Influenza, E. coli, Clostridium difficile)
 Utilize Salmonella-based vectors for delivery of immunotherapy
treatments for Cancer (preliminary data available)
 Exploration funded by multiple grants through Dr. Curtiss’s lab at
University of Florida
14
HealthCare
A New World of Health

15. Management Team
 Thomas Bigger - CEO/President/Co-Founder
 Experienced biotechnology executive
 Decades of infectious disease experience
 Roy C. Curtiss lll - CSO/Co-Founder
 World class scientist – National Academy of Sciences member, life-time
member American Society of Microbiology
 Recognized world expert “has played a seminal role in the Salmonella Vaccine
field for at least 30 years”
 Substantial NIH and Gates funding
 Decades of experience in developing live vaccines
 Dennis Molnar - CFO/VP Commercial Development
 Experienced biotechnology executive
 Decades of infectious disease experience
 Robert Nordgren – Technical Research Advisor
 Experienced animal health executive
 32 years of experience in developing vaccines for animal health
15
HealthCare
A New World of Health

16. Funding the Future for Curtiss Healthcare
3 Phase Funding Plan:
 Seed funding = $1.4 - $1.7 million
 Funds lab start-up & lead program hand-off to partner – C. perfringens
 Series A over next 3 - 4 years = $12 - $15 million
 Funds next 4 - 5 avian & swine program development to milestones
 Milestones & grants >4 years provide sustained funding (+cash flow)
 Development in swine/cattle and emerging human programs funded
16 HealthCare
A New World of Health